Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Vortioxetine in major depression: high success rates, acceptable cost

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      The SOLUTION trial was supported by H. Lundbeck A/S.

    Reference

    1. Wang G, et al. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Current Medical Research and Opinion : 28 Jan 2020. Available from: URL: https://doi.org/10.1080/03007995.2020.1723072

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Vortioxetine in major depression: high success rates, acceptable cost. PharmacoEcon Outcomes News 846, 31 (2020). https://doi.org/10.1007/s40274-020-6570-6

    Download citation